Accessibility Menu
WuXi Biologics (Cayman) logo

WuXi Biologics (Cayman)(OTC) WXIBF

Current Price$4.60
Market Cap$19.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-33%
5 Year-72%
1 Year+21%
1 Month+15%
WuXi Biologics (Cayman) last closing stock price
MetricPriceDate
Last closeUSD 4.602026-07-24
WuXi Biologics (Cayman) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 4.602026-07-17
1 month+15%USD 4.002026-06-24
3 month-2.13%USD 4.702026-04-24
Year to date+9%USD 4.222025-12-26
1 year+21.05%USD 3.802025-07-24
3 year-11.71%USD 5.212023-07-24
5 year-72.27%USD 16.592021-07-23
Since inception-33.33%USD 6.902018-01-30

WuXi Biologics (Cayman) Financials at a Glance

Market Cap

$19.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥40.27B

Net Income (TTM)

CN¥8.22B

EPS (TTM)

$0.16

P/E Ratio

27.50

Dividend

$0.00

Beta (Volatility)

0.40 (Low)

Price

$4.60

Volume

990

Open

$4.60

Previous Close

$4.60

Daily Range

$4.60 - $4.60

52-Week Range

$3.80 - $5.61

Estimated Earnings Date

Aug 26, 2026

WXIBF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About WuXi Biologics (Cayman)

WuXi Biologics (Cayman) Inc. is a leading global provider of comprehensive services for the biopharmaceutical industry, covering the entire spectrum from drug discovery to advanced development and manufacturing. The company serves clients across China, North America, Europe, and other international markets, offering expertise in biopharmaceutical technology and contract development.

Products and Services
  • Comprehensive biopharmaceutical services from discovery to manufacturing
  • Contract development and manufacturing organization (CDMO) for vaccines
  • Advanced testing services and expert consultation in biopharmaceutical technology
Growth Outlook
  • Revenue increased to CNY 11.64 billion in Q4 2025, up from CNY 9.95 billion in Q2 2025
  • Net income rose to CNY 2.53 billion in Q4 2025, reflecting strong operational efficiency
  • Strategic collaborations with major partners enhance market position and growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 39.5 billion, indicating robust demand
  • Operating income margin of 33.14% demonstrates effective cost management
  • Current ratio of 3.14 suggests strong liquidity and financial stability
WuXi Biologics has established itself as a key player in the biotechnology sector, leveraging its extensive service offerings to meet the growing demands of the biopharmaceutical industry. The company's recent financial performance highlights its ability to generate significant revenue and maintain strong profit margins, positioning it well for future growth. With a solid foundation and strategic partnerships, WuXi Biologics is poised to capitalize on the expanding global biopharmaceutical market.
AI Generated • Jun 30, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

13,252

CEO

Zhi Sheng Chen, PhD

Website

www.wuxibiologics.com

Headquarters

Wuxi, JS 214092, CN

WXIBF Financials

Key Financial Metrics (TTM)

Gross Margin

45.98%

Operating Margin

30.47%

Net Income Margin

22.53%

Return on Equity

10.64%

Return on Capital

12.85%

Return on Assets

7.70%

Earnings Yield

3.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.14B

Volume

990

Avg. Volume

2.43K

Financials (TTM)

Gross Profit

CN¥17.57B

Operating Income

CN¥11.56B

EBITDA

CN¥14.61B

Operating Cash Flow

CN¥11.62B

Capital Expenditure

-CN¥7.64B

Free Cash Flow

CN¥3.98B

Cash & ST Invst.

CN¥15.75B

Total Debt

CN¥3.11B

WuXi Biologics (Cayman) Performance Analysis

WuXi Biologics (Cayman) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 2,267,494,59642.1%
20232023-12-31CNY 2,404,260,5846.0%
20242024-12-31CNY 2,594,948,5077.9%
20252025-12-31CNY 3,031,254,84316.8%
WuXi Biologics (Cayman) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-300.4%
Q42024-12-3117.8%
Q22025-06-30-1.5%
Q42025-12-3116.9%
WuXi Biologics (Cayman) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.1526.3%
20232023-12-31CNY 0.11-27.3%
20242024-12-31CNY 0.11-0.1%
20252025-12-31CNY 0.1648.2%
WuXi Biologics (Cayman) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3034.6%
Q42024-12-3122.9%
Q22025-06-3027.9%
Q42025-12-319.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥11.64B

+36.3%

Gross Profit

CN¥5.67B

+73.5%

Gross Margin

48.71%

N/A

Market Cap

$19.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.44M

N/A

Employees

13,252

N/A

Net Income

CN¥2.53B

+123.0%

EBITDA

CN¥4.73B

+122.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥15.75B

+40.0%

Total Debt

CN¥3.11B

-31.9%

Accounts Receivable

CN¥8.90B

+43.9%

Inventory

CN¥1.44B

-18.4%

Long Term Debt

CN¥1.85B

-51.7%

Short Term Debt

CN¥1.26B

+71.7%

Return on Assets

7.70%

N/A

Return on Invested Capital

11.98%

N/A

Free Cash Flow

CN¥2.79B

+1176.6%

Operating Cash Flow

CN¥4.60B

+97.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SAUHFStraumann Holding AG
$118.30-2.99%
IVBXFInnovent Biologics, Inc.
$10.83-15.39%
SAUHYStraumann Holding AG
$11.64-1.02%
GNMSFGenmab A/S
$274.50+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About WXIBF

What is the current price of WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) is trading at $4.60 per share.

What is the 52-week range for WuXi Biologics (Cayman)?

Over the past 52 weeks, WuXi Biologics (Cayman) has traded between $3.80 and $5.61.

How much debt does WuXi Biologics (Cayman) have?

As of the most recent reporting period, WuXi Biologics (Cayman) reported total debt of CN¥444.19M.

How much cash does WuXi Biologics (Cayman) have on hand?

WuXi Biologics (Cayman) reported CN¥1.32B in cash and cash equivalents in its most recent financial results.

What is WuXi Biologics (Cayman)’s dividend yield?

WuXi Biologics (Cayman) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services